Five weeks after the declaration of the Ebola Bundibugyo outbreak in the Democratic Republic of Congo, the virus continues to defy containment efforts. Despite a significant ramp-up in the response, the epidemic remains ahead of health workers, steadily advancing, crossing borders, and claiming lives.
Intensified response still falling short
Considerable progress has been made. Bed capacity in treatment centres has surged from fewer than 10 to over 500 across 19 facilities in affected areas. Testing capacity has similarly expanded—from 30 daily tests at the start to more than 2,000 per day in nine laboratories spanning three provinces. Over 100 patients have recovered, underscoring the life-saving potential of early care.
Yet the toll remains severe: 1,094 confirmed cases and 277 deaths to date. World Health Organization Director-General Tedros Adhanom Ghebreyesus has warned that the outbreak continues to outpace the response. Contact tracing is insufficient, isolation capacity is inadequate, and safe burials remain a daily struggle in communities that are often sceptical or hard to reach.
A virus that ignores borders
The outbreak has now expanded well beyond the Congolese provinces of Ituri, North Kivu and South Kivu. Neighbouring Uganda has reported 20 confirmed cases and two deaths, all linked to the Congolese strain. More alarmingly, France confirmed its first case on European soil this Wednesday: a humanitarian doctor from the NGO ALIMA who returned from a mission in DRC tested positive for Ebola Bundibugyo. He is being treated in a specialised facility and is in stable condition. An epidemiological investigation is underway to trace and monitor his contacts.
This case is a stark reminder of the price paid by frontline health workers. Nearly 80 medical staff have been infected since the crisis began, prompting the WHO to call on states to ensure secure working conditions for humanitarian personnel, including the possibility of rapid medical evacuation in the event of infection.
Response hampered by funding gaps and insecurity
Beyond health challenges, the response is hampered by structural obstacles that complicate every intervention. Border closures restrict the movement of teams and equipment. Security incidents are on the rise in a region scarred by decades of armed conflict. Funding has been slow to materialise, even as the WHO and Africa CDC have launched a continental plan estimated at 518 million dollars.
One glimmer of hope: a clinical trial evaluating two antivirals, MBP134 and remdesivir, is set to begin next week in DRC. Led by a consortium that includes the National Institute of Biomedical Research of DRC, ALIMA, the University of Oxford, and the WHO, with support from donations from the United States and Gilead Sciences, this trial could mark a decisive turning point against an outbreak that, five weeks after its start, remains far from contained.
